Mark S. Shearman. Ongoing Progress in the Phase 1/2 BRILLIANCE Clinical Trial for Treatment of CEP-290 Retinal Degeneration: In vivo CRISPR gene editing therapies for ocular disease. Presented at TIDES USA Oligonucleotide & Peptide Therapeutics. May 9 – 13, 2022.